Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) have radically improved survival outcomes for metastatic melanoma patients. Here, CTLA4 is linked to metastatic melanoma.